Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers
NCT02173717 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2014-06-25
Summary
Study to investigate whether and to what extent the suggested P-glycoprotein (P-gp) inducer rifampicin affects plasma exposure of dabigatran.
Conditions
- Healthy
Interventions
- DRUG
-
Dabigatran etexilate
150 mg Dabigatran etexilate
- DRUG
-
Rifampicin
600 mg Rifampicin
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-06-30
- Primary Completion
- 2009-07-31
More Related Trials
-
Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers
NCT02044367 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers
NCT02171533 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability of Dabigatran and Amiodarone After Multiple Oral Administrations of Dabigatran Etexilate With or Without Amiodarone as Single Dose in Healthy Male and Female Volunteers
NCT02171026 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults
NCT05673889 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions
NCT02367027 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects
NCT04092725 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects
NCT02710630 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy Subjects
NCT02182037 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants
NCT05123079 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects
NCT01289509 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet
NCT01853800 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers
NCT02259881 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects
NCT04511611 ·Status: COMPLETED ·Phase: PHASE1
-
A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants
NCT02117505 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin
NCT01770392 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects
NCT04511637 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food
NCT01286571 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment
NCT01126086 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers
NCT02183389 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
NCT01464450 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects
NCT02034565 ·Status: COMPLETED ·Phase: PHASE1
-
Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects
NCT02254083 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems
NCT05661344 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants
NCT04720092 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
NCT02034578 ·Status: COMPLETED ·Phase: PHASE1